TG Therapeutics (TGTX) Earnings Analysis

TG Therapeutics (TGTX) next reports earnings on 2026-08-03, consensus EPS 0.3171 USD. Last quarter (2026-02-26) it missed with EPS 0.14 USD vs 0.35 USD est (-60%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 16.57.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TGTX next report earnings?

Next earnings date2026-08-03
Consensus EPS estimate0.3171 USD
Revenue estimate0.23B

TGTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-260.14 USD0.35 USD-60%Miss
2025-11-032.43 USD0.24 USD+912.5%Beat
2025-08-040.17 USD0.32 USD-46.9%Miss
2025-05-050.03 USD0.18 USD-83.3%Miss
2025-03-030.15 USD0.08 USD+87.5%Beat
2024-11-040.02 USD0.03 USD-33.3%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

TGTX valuation and analyst view

Trailing P/E16.57
Trailing EPS3.198 USD
Price / book13.05
Dividend yield0.00%
Market cap8.12B
Analyst consensusBuy (11 buy / 1 hold / 1 sell)
Avg price target76.5 USD

Related research pages

Frequently asked questions

When is TG Therapeutics (TGTX)'s next earnings date?

TG Therapeutics is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 0.3171 USD and revenue estimate of 0.23B.

Did TGTX beat earnings last quarter?

In its 2026-02-26 report, TGTX posted EPS of 0.14 USD versus a 0.35 USD estimate — a miss of 60%.

What is TGTX's earnings track record?

Over the last 6 reported quarters with consensus data, TGTX beat estimates 2 times (33%).

What is TGTX's current P/E ratio and EPS?

TGTX trades at a trailing P/E of 16.57 on trailing EPS of 3.197853881528284 USD.

What do analysts rate TGTX?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 11 buy, 1 hold, 1 sell, 0 strong sell). Average 12-month price target: 76.5 USD.